Original reporting and analysis on the stories shaping biotech.
About 6,000 women enter menopause daily in the U.S., and the market opportunity tops $120 billion. So why does the pharmaceutical industry keep stumbling on drugs for it? The answer involves ghost studies, broken trial designs, and a system that still treats half the population's health as a niche.
A Shanghai biotech just raised $110 million to chase what nobody has achieved: a CAR-T therapy that actually works against solid tumors. Oricell Therapeutics is betting it can crack liver cancer and IPO on the other side.
Analysts are calling lipoprotein(a) inhibitors biotech's next blockbuster category, with comparisons to the GLP-1 obesity gold rush. With 65 million eligible U.S. patients and zero approved treatments, the first definitive trial results are expected this summer.
Researchers found that toxic sugars made by gut bacteria can trigger ALS and frontotemporal dementia by sparking immune attacks on the brain. The discovery could explain why some people with high-risk genes never get sick, and clinical trials targeting this gut-brain pathway could begin within a year.
Life Biosciences just raised $80 million to test whether a gene therapy can literally rejuvenate aging cells inside the human eye. It's the first epigenetic reprogramming therapy to reach human trials, and the implications go way beyond glaucoma.
Novo Nordisk just bet up to $2.1 billion on a 40-person MIT spinout that built a miniature gut on a chip. The deal could reshape how obesity drugs reach patients, and it signals that the next frontier in the weight-loss wars isn't a new molecule; it's a better pill.
Roche just deployed 2,176 NVIDIA Blackwell GPUs, building the largest supercomputer any pharma company has ever announced. The move signals that computational firepower is becoming as critical as lab equipment in the race to discover new drugs.
Avalyn Pharma just filed for a $100 million IPO to fund inhaled versions of existing lung disease drugs. Early data suggests its approach could slash side effects while preserving efficacy, but the company is betting public investors will back a Phase 2 story in a market that's been rewarding only the safest bets.
Akari Therapeutics just partnered with WuXi XDC to manufacture its cancer drug, right as Washington tightens the screws on Chinese biotech. The preclinical data looks promising, but the geopolitical math is anything but simple.
The U.S. can't domestically produce basic antibiotics like penicillin, with over 70% of active ingredients sourced from China. Now the federal government is paying Shionogi up to $482 million to change that, and the reasons go way beyond hospital infections.
Roche just committed over $1 billion in potential milestones to co-develop cancer-killing "guided missiles" with C4 Therapeutics. The same week, Gilead made its own protein degradation bet. When two pharma giants pile into the same modality within 24 hours, it's worth paying attention.
Gilead just paid $45 million to license a cancer drug that doesn't block bad proteins; it destroys them entirely. The Kymera Therapeutics deal could be worth up to $750 million, and it's part of a much bigger bet on protein degradation reshaping oncology.
Novo Nordisk launched a higher-dose Wegovy at $399 per month, undercutting Eli Lilly's Zepbound by 40% and igniting an all-out pricing war in the obesity drug market. With subscription plans as low as $249/month and 20.7% weight loss in trials, the GLP-1 landscape is being rewritten in real time.
The most safety-conscious AI company in tech just got kicked out of federal healthcare systems. Not for a security flaw, but for refusing to let the Pentagon use its tools without guardrails. The fallout for drug development could set the FDA back 18 months.
Biogen just partnered with Alloy Therapeutics to access a platform that literally reshapes antisense drugs at the molecular level. It's a quiet deal that could unlock targets the company's existing toolkit can't touch.
Sidewinder Therapeutics just raised $137 million without ever dosing a patient. Its bispecific ADC platform has big pharma's venture arms lining up, and the math behind the bet says a lot about where oncology dealmaking is headed.
Jeito Capital just closed the largest fund ever raised by an independent European biopharma investor: $1.2 billion. It's a massive bet that Europe can stop watching its best biotech companies get scooped up by American money.
A University of Michigan team just proved that triglycerides directly cause a deadly condition with zero approved drugs, then showed they could prevent it in mice. The finding could unlock an entirely new class of treatment for 200,000 Americans a year.
Anthropic just dropped $400 million in stock to acquire a stealth biotech startup with no product, no revenue, and fewer than 10 employees. The deal netted one early investor a jaw-dropping 38,513% return, and it signals a brand-new front in the AI-biotech arms race.
Neurocrine Biosciences just dropped $2.9 billion on Soleno Therapeutics to own the only approved drug for Prader-Willi syndrome's life-threatening hunger. The deal says a lot about what big pharma is willing to pay in 2026's red-hot M&A market.
Gilead just agreed to pay $3.15 billion (and up to $5 billion total) for a Munich startup most people have never heard of. Tubulis' "guided missile" cancer drugs caught Gilead's eye with a 59% response rate in hard-to-treat ovarian cancer, and the deal says everything about where oncology is headed.
Replimune's tumor-killing virus drug faces a make-or-break FDA decision on April 10, but the agency that rejected it last year has lost nearly every leader who made that call. The approval has become a litmus test for whether the FDA can still function amid unprecedented turmoil.
Join thousands of biotech professionals who start their day with our free, daily briefing.